Overview

Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of the Fully Human Anti-tetanus Toxin Monoclonal Antibody A82 / B86 Injection Combination Formulation

Status:
NOT_YET_RECRUITING

Trial end date:
2024-10-30

Target enrollment:

Participant gender:

Summary

To evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and immunogenicity of the full human anti-tetanus toxin monoclonal antibody A82 / B86 injection combination formulation

Phase:

EARLY_PHASE1

Details

Lead Sponsor:

Changchun BCHT Biotechnology Co.

Collaborators:

Anning City First People's Hospital
The First Affiliated Hospital of Yunnan University of Traditional Chinese Medicine